Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the market grown in recent years?

The market for Tay-Sachs disease treatment has seen significant growth in the past few years. Its size is expected to increase from $2.28 billion in 2024 to around $2.45 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.5%. Factors contributing to this notable growth during the historic period include enhanced genetic screening, elevated focus on rare diseases, increased demand for high-quality healthcare, a rise in Tay-Sachs disease incidences, and an upsurge in cases of chronic conditions.

How is the market size expected to evolve during the forecast period?

In the forthcoming years, the tay-sachs disease treatment market is predicted to experience notable growth, with an expected increase to $3.25 billion in 2029 and a compound annual growth rate (CAGR) of 7.3%. This projected growth in the forecast period is due to factors such as an increase in lysosomal storage disorders, the rise of awareness programs, the expansion of genetic testing services, a surge in demand for symptomatic treatments, and an escalating number of genetic diseases. The forecast period will also see key trends such as improvements in gene therapy, cost-effectiveness of next-gen sequencing, automation in cloning platforms, advancements in drug delivery systems, incorporation of AI and machine learning, and the utilization of telemedicine solutions.

Get your market report here!

https://www.thebusinessresearchcompany.com/report/tay-sachs-disease-treatment-global-market-report

What key factors are fueling the growth of the market?

The escalating incidence of genetic disorders is predicted to propel the tay-sachs disease treatment market in the future. Genetic disorders are conditions triggered by discrepancies in an individual’s DNA, which could be inherited or come about due to random mutations. The rising numbers of genetic disorders is attributed to factors such as improved diagnostic techniques, heightened awareness, environmental influences, and increased mutation rates because of delayed parenthood and lifestyle modifications. These rising numbers stress the urgency for improvements in tay-sachs disease treatment, spurring studies in gene therapy, enzyme replacement, and early diagnostics. For example, as stated by Genomics England, a governmental organization in the UK, in February 2022, there are over 7,000 acknowledged rare diseases, affecting approximately 1 in 17 people (3.5 million) in the UK. Hence, the rising incidence of genetic disorders will propel the tay-sachs disease treatment market.

What are the market segments in the industry?

The tay-sachs disease treatment market covered in this report is segmented –

1) By Treatment: Medication, Respiratory Care, Physical Therapy

2) By Mode Of Administration: Injectable, Oral, Other Mode Of Administration

3) By End-Users: Hospitals, Homecare, Specialty Clinics

Subsegments:

1) By Medication: Antiepileptic Drugs, Miglustat, Supportive Symptomatic Medications

2) By Respiratory Care: Mechanical Ventilation, Airway Clearance Therapy, Oxygen Therapy

3) By Physical Therapy: Motor Function Exercises, Hydrotherapy, Assistive Mobility Devices

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21295&type=smp

Which leading companies are shaping the growth of the market?

Major companies operating in the tay-sachs disease treatment market are Pfizer Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Amicus Therapeutics Inc., Spark Therapeutics Inc., Rocket Pharmaceuticals Inc., RegenxBio Inc., Forge Biologics Inc., Passage Bio Inc., Protalix BioTherapeutics Inc., Orchard Therapeutics plc, Affinia Therapeutics Inc., IntraBio Inc., Taysha Gene Therapies Inc.

What are the key trends shaping the future of the market?

Leading enterprises in the tay-sachs disease treatment market are focusing on developing advanced treatment methods. Their efforts range from conducting clinical trials to exploring modern therapy techniques like gene therapy, enzyme substitutes, and tiny particle drugs to enhance patient results. Clinical trials are research studies assessing the safety, effectiveness, and potential adverse effects of medical treatments, medications, or procedures on humans. For example, in July 2024, IntraBio Inc., a biopharmaceutical firm based in the United States, disclosed receiving FDA approval for its IND Application to hold a clinical trial (IB1001-202) intended for IB1001, which is aimed at GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease). The trial is being conducted in the US, UK, Germany, and Spain, intending to address fatal neurodegenerative disorders that currently lack approved treatments. The chairman of IntraBio highlighted the expedited need for the development of effective therapies for these debilitating diseases.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21295

Which geographic areas are influencing the growth of the market?

North America was the largest region in the tay-sachs disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tay-sachs disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Convalescent Plasma Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/convalescent-plasma-therapy-global-market-report

Plasma Fractionation Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report

Plasma Protein Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: